A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia

• Status: Completed
• Trial end date: 2008-12-23
• Target enrollment: 0
• Participant gender: All

Summary

Pregabalin is an alpha-2 delta ligand approved for the treatment of neuropathic pain, however, not all patients will respond to this drug. This study will compare the efficacy of pregabalin when administered with an experimental drug PF-00489791, in patients with post-herpetic neuralgia. The efficacy of this combination will be compared to pregabalin alone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Male or female of non-childbearing potential

• Pain present for more than 3 months after healing of herpes zoster skin rash

• VAS score of >=40mm at screening and baseline visits

Exclusion Criteria:

• Patients with pain conditions which might impair the assessment of postherpetic neuralgia

• Skin conditions in the affected dermatome that could alter sensation other than postherpetic neuralgia

• History or diagnosis of DSM IV major depressive disorder